tranexamic acid

(redirected from Lysteda)
Also found in: Medical.

tranexamic acid

[¦tran·ik¦sam·ik ′as·əd]
(pharmacology)
C8H15NO2 Crystals which soften at 270°C and are soluble in water; used as a hemostatic agent. Abbreviated AMCHA.
Mentioned in ?
References in periodicals archive ?
M2 EQUITYBITES-January 4, 2013-Watson Pharmaceuticals Inc wins US FDA approval for generic Lysteda for treating cyclic heavy menstrual bleeding(C)2013 M2 COMMUNICATIONS http://www.
9-g/day dosage of Lysteda to treat heavy menstrual bleeding based on results from the pivotal trials (Obstet.
FDA approval of Lysteda confirms the efficacy and tolerability of the agent and provides physicians with a reliable option for the management of HMB.
has received approval of its ANDA for tranexamic acid tablets, the generic equivalent to Ferring Pharmaceuticals' Lysteda, indicated for treating cyclic heavy menstrual bleeding.
The oral formulation was approved by the Food and Drug Administration late last year for the treatment of cyclic heavy menstrual bleeding and is marketed under the trade name Lysteda.
He reports nothing to disclose in regard to Ferring Pharmaceuticals, the manufacturer of Lysteda (tranexamic acid).
The FDA has approved Lysteda, an oral form of tranexamic acid, for the treatment of menorrhagia.
It is Ferring's second major investment in the therapeutic field in two years, having purchased the global marketing rights for LYSTEDA (tranexamic acid) for the treatment of heavy menstrual bleeding, in May 2010.
Disclosures: The study was funded by Xanodyne Pharmaceuticals and Ferring Pharmaceuticals, which acquired global marketing rights to Lysteda last May.
The Food and Drug Administration approved Lysteda, a proprietary form of tranexamic acid, for the treatment of menorrhagia.
The Food and Drug Administration has approved Lysteda, a proprietary form of tranexamic acid, for the treatment of menorrhagia.